nach oben

Journal of General Internal Medicine

Erschienen in:

01.04.2020 | Perspective

On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know

verfasst von: Parya Saberi, PharmD, MAS, Hyman M. Scott, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Based on the results of the IPERGAY study, on-demand HIV pre-exposure prophylaxis (PrEP; also known as “non-daily PrEP,” “event-driven PrEP,” or “2-1-1 PrEP”) is being requested more frequently by patients who have intermittent sexual risk or are unable/unwilling to take daily PrEP; therefore, clinicians will be increasingly required to familiarize themselves with its appropriate use. In this perspective, we summarize data related to on-demand PrEP, describe advantages and disadvantages for this alternative dosing strategy, and provide clinical counseling points.

Molina JM, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. New Engl J Med. 2015;373(23):2237–2246.CrossRef

Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet Hiv. 2017;4(9):E402-E410.CrossRef

Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Sci Transl Med. 2012;4(151).

Grant RM, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New Engl J Med. 2010;363(27):2587–2599.CrossRef

Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379–396.CrossRef

Fauci A. Ending the HIV Epidemic: a plan for the united states (Abstract #2010). Conference on Retroviruses and Opportunistic Infections (CROI); 2019.

Marcus JL, Levine K, Grasso C, et al. HIV Preexposure Prophylaxis as a Gateway to Primary Care. Am J Public Health. 2018;108(10):1418–1420.CrossRef

Whitfield THF, Jones SS, Wachman M, Grov C, Parsons JT, Rendina HJ. The Impact of Pre-Exposure Prophylaxis (PrEP) Use on Sexual Anxiety, Satisfaction, and Esteem Among Gay and Bisexual Men. J Sex Res. 2019:1–8.

Mabire X, Puppo C, Morel S, et al. Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation. Am J Mens Health. 2019;13(1).

10.

Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. Aids Behav. 2014;18(2):226–240.CrossRef

11.

Calabrese SK, Krakower DS, Mayer KH. Integrating HIV Preexposure Prophylaxis (PrEP) Into Routine Preventive Health Care to Avoid Exacerbating Disparities. Am J Public Health. 2017;107(12):1883–1889.CrossRef

12.

Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–849.CrossRef

13.

Finlayson T, Cha SS, Xia M, et al. Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men-20 Urban Areas, 2014 and 2017. Mmwr-Morbid Mortal W. 2019;68(27):597–603.CrossRef

14.

Huang YLA, Zhu WM, Smith DK, Harris N, Hoover KW. HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016. Mmwr-Morbid Mortal W. 2018;67(41):1147–1150.CrossRef

15.

Auerbach JD, Hoppe TA. Beyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV. J Int Aids Soc. 2015;18(4 Suppl 3):19983.CrossRef

16.

Zimmermann HM, Eekman SW, Achterbergh RC, et al. Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis - a qualitative analysis. J Int Aids Soc. 2019;22(10):e25389.CrossRef

17.

Durand-Zaleski I, Mutuon P, Charreau I, et al. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM. Aids. 2018;32(1):95–102.CrossRef

18.

Liegeon G, Antoni G, Pialoux G, et al. Changes in kidney function among MSM initiating on-demand TDF/FTC for HIV PrEP (Abstract #960). Paper presented at: Conference on Retrovirusis and Opportunistic Infections2019; Seattle, WA.

19.

Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. Aids. 2010;24(7):1064–1066.CrossRef

20.

Anderson PL, Garcia-Lerma JG, Heneine W. Nondaily preexposure prophylaxis for HIV prevention. Current opinion in HIV and AIDS. 2016;11(1):94–101.CrossRef

21.

Volk JE, Liu A, Vittinghoff E, et al. Sexual Frequency and Planning Among At-Risk Men Who Have Sex With Men in the United States: Implications for Event-Based Intermittent Pre-Exposure Prophylaxis. Jaids-J Acq Imm Def. 2012;61(1):112–115.CrossRef

22.

Kibengo FM, Ruzagira E, Katende D, et al. Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial. Plos One. 2013;8(9).

23.

Hiransuthikul A., Himmad K., Kerr S, et al. Drug-drug interactions between the use of feminizing hormone therapy and pre-exposure prophylaxis among transgender women: The iFACT study. Paper presented at: AIDS 20182018; Amsterdam, The Netherlands.

24.

Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol. 2014;20(43):16053–16061.CrossRef

25.

Di Ciaccio M, Protiere C, Castro DR, et al. The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the "participant"-physician relationship. Aids Care. 2018;30:41–47.CrossRef

Titel: On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know
verfasst von: Parya Saberi, PharmD, MAS
Hyman M. Scott, MD
Publikationsdatum: 01.04.2020
Verlag: Springer International Publishing
Erschienen in: Journal of General Internal Medicine / Ausgabe 4/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-020-05651-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Sexism and Sexual Harassment in Medicine: Unraveling the Web

Physician-Nurse Practitioner Teamwork in Primary Care Practices in New York: A Cross-Sectional Survey

SAPHO Syndrome from Hidradenitis Suppurativa

Challenges of Measuring Costs of Care for US Practices

A Community of Practice for Teaching the Social Determinants of Health in Undergraduate Medical Education

Time and Organizational Cost for Facilitating Implementation of Primary Care Mental Health Integration

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin